Aurinia Pharmaceuticals Inc (AUPH) concluded trading on Thursday at a closing price of $8.63, with 3.51 million shares of worth about $30.29 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -4.43% during that period and on June 26, 2025 the price saw a gain of about 7.47%. Currently the company’s common shares owned by public are about 137.75M shares, out of which, 119.37M shares are available for trading.
Stock saw a price change of 8.96% in past 5 days and over the past one month there was a price change of 5.89%. Year-to-date (YTD), AUPH shares are showing a performance of 52.47% which decreased to -3.90% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $5.20 but also hit the highest price of $10.67 during that period. The average intraday trading volume for Aurinia Pharmaceuticals Inc shares is 1.22 million. The stock is currently trading 7.12% above its 20-day simple moving average (SMA20), while that difference is up 7.10% for SMA50 and it goes to 7.85% higher than SMA200.
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) currently have 137.75M outstanding shares and institutions hold larger chunk of about 45.03% of that.
The stock has a current market capitalization of $1.17B and its 3Y-monthly beta is at 1.16. PE ratio of stock for trailing 12 months is 31.25, while it has posted earnings per share of $0.28 in the same period. It has Quick Ratio of 5.26 while making debt-to-equity ratio of 0.22. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AUPH, volatility over the week remained 4.55% while standing at 2.90% over the month.
Stock’s fiscal year EPS is expected to rise by 1365.00% while it is estimated to increase by 29.35% in next year.
Coverage by Cantor Fitzgerald stated Aurinia Pharmaceuticals Inc (AUPH) stock as an Overweight in their note to investors on May 05, 2022, suggesting a price target of $25 for the stock. On December 10, 2021, Oppenheimer Upgrade their recommendations, while on October 28, 2021, Oppenheimer Downgrade their ratings for the stock with a price target of $32. Stock get a Buy rating from H.C. Wainwright on January 25, 2021.
